Latest Articles
Michelle Ackerley Announces Pregnancy Live After Infertility Battle - evrimagaci.org
Michelle Ackerley Announces Pregnancy Live After Infertility Battle evrimagaci.org
Published: May 7, 2025, 12:29 p.m.
Dr. Karli Provost Goldstein Named to 2025 New York Rising Stars List for Fourth Consecutive Year - PharmiWeb.com
Dr. Karli Provost Goldstein Named to 2025 New York Rising Stars List for Fourth Consecutive Year PharmiWeb.com
Published: May 7, 2025, 12:28 p.m.
Two gynecologists punished for research misconduct - China Daily
Two gynecologists punished for research misconduct China Daily
Published: May 7, 2025, 12:28 p.m.
Uterine Cancer Survival Varies Widely by Race Across US - Medscape
Uterine Cancer Survival Varies Widely by Race Across US Medscape
Published: May 7, 2025, 12:27 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
Mayo Clinic Q and A: Postsurgery recovery for women, what to know with endometriosis - Mayo Clinic News Network
Mayo Clinic Q and A: Postsurgery recovery for women, what to know with endometriosis Mayo Clinic News Network
Published: May 7, 2025, 12:17 p.m.
Dr. Karli Provost Goldstein Named to 2025 New York Rising Stars List for Fourth Consecutive Year - Newswire.com
Dr. Karli Provost Goldstein Named to 2025 New York Rising Stars List for Fourth Consecutive Year Newswire.com
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스
Published: May 7, 2025, noon
Drug Discovery Science Articles | Page 83 - Technology Networks
Drug Discovery Science Articles | Page 83 Technology Networks
Published: May 7, 2025, 11:32 a.m.
Link copied to clipboard!